Table 2.
Tissue and plasma molecular diagnostics.
| Characteristics | Patients, N (%) | |||
|---|---|---|---|---|
| Number of Patients | 73 (100.0%) | |||
| Diagnostic techniques, N (%) | ||||
| Tissue, 73 (100.0%) |
Real-time PCR, | 55 (75.3%) | WT, 44 (80.0%) | |
| Mutated, 11 (20.0%) | EGFR—8, BRAF—3 | |||
| NGS | 9 (12.3%) | WT, 3 (33.3%) | ||
| Altered, 6 (66.6%) | EGFR—2, KRAS—2, ALK—1, MET—1, RET—1, ROS1—1 | |||
| NA | 13 (17.8%) | – | – | |
| Plasma, 10 (13.6%) |
Droplet digital PCR | 5 (50.0%) | WT, 3 (60.0%) | |
| Mutated, 2 (40.0%) | EGFR—2 | |||
| NGS | 5 (50.0%) | WT, 0 (0.0%) | ||
| Altered, 5 (100.0%) | EGFR—2, BRAF—1, KRAS—1, EGFR + TP53—1 | |||
| Tissue predictive biomarker testing, N (%) | ||||
| IHC | PD-L1, 67 (91.7%) |
≥50% 1–49% <1% N/A |
16 (21.9%) 27 (36.9%) 24 (32.8%) 6 (8.2%) |
|
| ALK, 56 (76.7%) |
Positive Negative N/A |
4 (5.4%) 52 (71.2%) 17 (23.2%) |
||
| ROS1, 46 (63.0%) |
Positive Negative N/A |
3 (4.1%)—1 confirmed by FISH (1.3%) 43 (58.9%) 27 (37.0%) |
||
| Molecular diagnostics | EGFR, 9 | p.E746_A750del, 3 p.E746_A750del + p.T790M + p.R175H, TP53, 1 p.E746_A750del + p.C797S, 1 p.L858R, 3 p.L861Q,1 |
||
| KRAS, 2 | p.G12V, 1 p.G12D, 1 |
|||
| BRAF, 3 | p.V600E, 3 | |||
| ROS1, 1 | ROS1-CD74, 1 | |||
| ALK, 1 | EML4-ALK, 1 | |||
| RET, 1 | KIF5B-RET, 1 | |||
| MET, 1 | Amplification, 1 | |||
| NTRK1/2/3, 0 | – | |||
| HER-2, 0 | – | |||
| Plasma predictive biomarker testing, N | ||||
| Molecular diagnostics | EGFR, 2 | p.E746_A750del, 1 p.E746_A750del + p.T790M + p.R175H, TP53; 1 |
||
| BRAF, 1 | p.V600E, 1 | |||
| KRAS, 1 | p.G12V, 1 | |||